Skip to content

INCY changes

Pick any two versions below to diff them.

View the full Nov 14, 2026 version
Price
$122.27 → $120.97(−1.1%)
Recent events
added: Nov 13, 2026: Incyte decided not to start MAESTRA-3, a planned Phase 3 study of INCB123667, its CDK2 inhibitor, with bevacizumab as first-line maintenance therapy in ovarian cancer. The study was to start in Q4 2026. Incyte said that the decision comes from the priorities of its development portfolio, not from safety or efficacy data, and that it does not change its financial guidance or its long-term outlook. Oct 29, 2026: Incyte reported Q3 2026 results. Total revenue rose 14% to $1.56 billion, and net sales rose 14% to $1.32 billion. It raised its 2026 net sales guidance to $5,210 million to $5,300 million. The release also said that the CHMP gave a positive opinion on povorcitinib in September, and that Incyte agreed with the US Centers for Medicare & Medicaid Services in August on Jakafi pricing for state Medicaid programs. Oct 29, 2026: Incyte filed its Form 10-Q for Q3 2026. It showed an acquired in-process research and development expense of $1,231.5 million for Vega. A loss of $784.8 million for the quarter followed. Cash, cash equivalents and marketable securities were $3.9 billion. Jul 6, 2026: Incyte completed its purchase of Vega Therapeutics for $1.25 billion in cash. Vega owns latarcibart, an anti-Protein S antibody in Phase 3 for von Willebrand disease. The seller can get up to $750 million more if sales reach milestones.